标题
Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-09-17
DOI
10.3389/fimmu.2021.717388
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Life-Saving, Dose-Adjusted, Targeted Therapy in a Patient with a STAT3 Gain-of-Function Mutation
- (2021) Eytan Sarfati et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib
- (2021) Shiyu Zhang et al. Pediatric Rheumatology
- Homeostatic regulation of STING by retrograde membrane traffic to the ER
- (2021) Kojiro Mukai et al. Nature Communications
- A Novel Biallelic STING1 Gene Variant Causing SAVI in Two Siblings
- (2021) Malak Ali Alghamdi et al. Frontiers in Immunology
- STING-Mediated Lung Inflammation and Beyond
- (2021) Marie-Louise Frémond et al. JOURNAL OF CLINICAL IMMUNOLOGY
- The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee
- (2021) Stuart G. Tangye et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib
- (2021) Pooja N. Patel et al. PEDIATRIC DERMATOLOGY
- Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3
- (2020) Nicole Mollé et al. BLOOD
- An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
- (2020) Gerd R. Burmester et al. DRUG SAFETY
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee
- (2020) Stuart G. Tangye et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy
- (2020) Conor Gruber et al. JOURNAL OF EXPERIMENTAL MEDICINE
- JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency
- (2020) Fahad Alsohime et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
- (2020) Susanne Adam et al. Science Translational Medicine
- Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
- (2020) Vijayabhaskar Veeravalli et al. DRUG SAFETY
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome
- (2020) Shaoling Zheng et al. Frontiers in Immunology
- Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
- (2020) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function
- (2020) Conor N. Gruber et al. IMMUNITY
- A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)
- (2020) Bin Lin et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome
- (2020) Zimu Deng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling
- (2020) Alice Lepelley et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors
- (2020) Alessia Pin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1
- (2020) Pui Y. Lee et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy
- (2020) Satoshi Okada et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient
- (2020) Oliver Wegehaupt et al. JOURNAL OF CLINICAL IMMUNOLOGY
- JAK Inhibition in a Patient with X-Linked Reticulate Pigmentary Disorder
- (2020) Corinne Légeret et al. JOURNAL OF CLINICAL IMMUNOLOGY
- STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition
- (2020) Natalia S. Chaimowitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus Kinase Inhibition in the Aicardi–Goutières Syndrome
- (2020) Adeline Vanderver et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early-onset autoimmunity associated with SOCS1 haploinsufficiency
- (2020) Jérôme Hadjadj et al. Nature Communications
- Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity
- (2020) Karima Alim et al. Expert Opinion on Drug Metabolism & Toxicology
- cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing
- (2020) Carolina Uggenti et al. NATURE GENETICS
- JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease
- (2020) Rachel Eisenberg et al. Journal of Allergy and Clinical Immunology-In Practice
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- (2020) William Damsky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients
- (2020) Marie-Louise Frémond et al. Journal of Allergy and Clinical Immunology-In Practice
- Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis
- (2020) Mark Yates et al. Arthritis & Rheumatology
- Self-Awareness: Nucleic Acid–Driven Inflammation and the Type I Interferonopathies
- (2019) Carolina Uggenti et al. Annual Review of Immunology
- Clinical aspects of STAT3 gain-of-function germline mutations: A Systematic Review
- (2019) Alexandre Fabre et al. Journal of Allergy and Clinical Immunology-In Practice
- Janus kinases to jakinibs: from basic insights to clinical practice
- (2019) Massimo Gadina et al. RHEUMATOLOGY
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
- (2019) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
- (2019) Diana S. Novikova et al. RHEUMATOLOGY INTERNATIONAL
- Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey
- (2019) Sibel Balci et al. CLINICAL IMMUNOLOGY
- Janus kinase inhibition for autoinflammation in patients with DNASE2 deficiency
- (2019) Ying Hong et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib
- (2019) Xiaolei Tang et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage
- (2019) Marie-Louise Frémond et al. THORAX
- Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity
- (2019) Sabine Jägle et al. CLINICAL IMMUNOLOGY
- Erythropoiesis defect observed in STAT3 GOF patients with severe anemia
- (2019) Andrea A. Mauracher et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2
- (2019) Christopher J. A. Duncan et al. Science Immunology
- Type I interferon pathway activation in COPA syndrome
- (2018) Stefano Volpi et al. CLINICAL IMMUNOLOGY
- Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations
- (2018) Jennifer W. Leiding et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- An open-label trial of JAK 1/2 blockade in progressive IFIH1 -associated neuroinflammation
- (2018) Kavitha Kothur et al. NEUROLOGY
- Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
- (2018) Lisa R. Forbes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Aicardi goutières syndrome is associated with pulmonary hypertension
- (2018) Laura A. Adang et al. MOLECULAR GENETICS AND METABOLISM
- Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency
- (2018) Coralie Briand et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of Ruxolitinib Therapy in a Patient with Severe Enterocolitis Associated with a STAT3 Gain of Function Mutation
- (2018) Marianna Parlato et al. GASTROENTEROLOGY
- JAK 1/2 Blockade in MDA5 Gain-of-Function
- (2018) Kirsty E. McLellan et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function Mutation
- (2018) Ayca Kiykim et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
- (2018) Denis Tvorogov et al. Science Advances
- Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib
- (2017) Tomoki Fukuyama et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome
- (2017) Kate L. Del Bel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Fatal ruxolitinib-related JC virus meningitis
- (2017) Begoña Ballesta et al. JOURNAL OF NEUROVIROLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
- (2017) Kei-ichiro Arimoto et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
- (2017) Nicolino Ruperto et al. Pediatric Rheumatology
- Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
- (2017) José Ramón Maneiro et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
- (2017) Kei-ichiro Arimoto et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease
- (2017) Ofer Zimmerman et al. Open Forum Infectious Diseases
- Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
- (2016) J. Toubiana et al. BLOOD
- Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea
- (2016) Chi A. Ma et al. BLOOD
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
- (2016) Sophia Maschalidi et al. BLOOD
- Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- (2016) Marie-Louise Frémond et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome
- (2016) Marije E.C. Meuwissen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pulmonary arterial hypertension exacerbated by ruxolitinib
- (2015) A. T. Low et al. HAEMATOLOGICA
- Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
- (2015) Eleanor Higgins et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis
- (2015) Levi B Watkin et al. NATURE GENETICS
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
- (2015) Mignon L. Loh et al. PEDIATRIC BLOOD & CANCER
- Pulmonary arterial hypertension exacerbated by ruxolitinib
- (2015) A. T. Low et al. HAEMATOLOGICA
- Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
- (2014) M. J. Kiel et al. BLOOD
- Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
- (2014) E. M. Haapaniemi et al. BLOOD
- Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
- (2014) J. D. Milner et al. BLOOD
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- (2014) Yan Beauverd et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations
- (2014) Nadia Jeremiah et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
- (2014) M Kontro et al. LEUKEMIA
- Activated STING in a Vascular and Pulmonary Syndrome
- (2014) Yin Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Organization of the ER–Golgi interface for membrane traffic control
- (2013) Federica Brandizzi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type I interferonopathies: a novel set of inborn errors of immunity
- (2011) Yanick J. Crow Annals of the New York Academy of Sciences
- Gain-of-function humanSTAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
- (2011) Luyan Liu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis
- (2011) Frank L. van de Veerdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search